THE CASE FOR HIGH-DOSE CHEMOTHERAPY - IS IT CHEMOTHERAPYS LAST GAMBLE

被引:5
作者
CANELLOS, GP [1 ]
机构
[1] HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA
来源
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1987年 / 23卷 / 04期
关键词
D O I
10.1016/0277-5379(87)90368-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:351 / 355
页数:5
相关论文
共 27 条
  • [1] ANTMAN K, 1986, ASCO P, V4, P40
  • [2] APPELBAUM FR, 1981, BLOOD, V58, P509
  • [3] MASSIVE CHEMOTHERAPY WITH NON-FROZEN AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN 13 CASES OF REFRACTORY HODGKINS-DISEASE
    CARELLA, AM
    SANTINI, G
    SANTORO, A
    COSER, P
    FRASSONI, F
    MARTINENGO, M
    NATI, S
    CONGIU, A
    GIORDANO, D
    CERRI, R
    DAMASIO, E
    LERCARI, G
    OCCHINI, D
    MARMONT, AM
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (05): : 607 - 613
  • [4] AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN THE TREATMENT OF POOR PROGNOSIS NON-HODGKINS LYMPHOMAS
    GORIN, NC
    NAJMAN, A
    DOUAY, L
    SALMON, C
    DAVID, R
    STACHOWIAK, J
    PARLIER, Y
    LOPEZ, M
    OPPENHEIMER, M
    LECOMTE, D
    DELOUX, J
    PETIT, JC
    PENE, F
    GEROTA, I
    VANDENAKKER, J
    DUHAMEL, G
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (02): : 217 - 225
  • [5] GORIN NC, 1986, BLOOD, V67, P1367
  • [6] HUMBLET Y, 1985, ASCO P, V4, P176
  • [7] HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR RELAPSED HODGKINS-DISEASE
    JAGANNATH, S
    DICKE, KA
    ARMITAGE, JO
    CABANILLAS, FF
    HORWITZ, LJ
    VELLEKOOP, L
    ZANDER, AR
    SPITZER, G
    [J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (02) : 163 - 168
  • [8] TUMOR BURDEN ASSESSMENT AND ITS IMPLICATION FOR A PROGNOSTIC MODEL IN ADVANCED DIFFUSE LARGE-CELL LYMPHOMA
    JAGANNATH, S
    VELASQUEZ, WS
    TUCKER, SL
    FULLER, LM
    MCLAUGHLIN, PW
    MANNING, JT
    NORTH, LB
    CABANILLAS, FC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) : 859 - 865
  • [9] KAISER H, 1985, BLOOD, V65, P1504
  • [10] KAIZER H, 1984, CANCER INVEST, V2, P203, DOI 10.3109/07357908409104373